Page 35 - AN-3-3

Advanced Neurology Tau pathology in murine TBI

33. Kahriman A, Bouley J, Smith TW, Bosco DA, Woerman AL, doi: 10.3390/biology10101047
Henninger N. Mouse closed head traumatic brain injury 43. Kelley CM, Perez SE, Mufson EJ. Tau pathology in the
replicates the histological tau pathology pattern of human
disease: Characterization of a novel model and systematic medial temporal lobe of athletes with chronic traumatic
review of the literature. Acta Neuropathol Commun. encephalopathy: A chronic effects of neurotrauma
consortium study. Acta Neuropathol Commun. 2019;7(1):207.
2021;9(1):118.
doi: 10.1186/s40478-019-0861-9
doi: 10.1186/s40478-021-01220-8
44. Mondragon-Rodriguez S, Perry G, Luna-Munoz J, Acevedo-
34. Yang Z, Wang P, Morgan D, et al. Temporal MRI
characterization, neurobiochemical and neurobehavioral Aquino MC, Williams S. Phosphorylation of tau protein at
changes in a mouse repetitive concussive head injury model. sites Ser(396-404) is one of the earliest events in Alzheimer’s
Sci Rep. 2015;5:11178. disease and down syndrome. Neuropathol Appl Neurobiol.
2014;40(2):121-135.
doi: 10.1038/srep11178
doi: 10.1111/nan.12084
35. Seo JS, Lee S, Shin JY, et al. Transcriptome analyses of
chronic traumatic encephalopathy show alterations in 45. Biernat J, Mandelkow EM. The development of cell
protein phosphatase expression associated with tauopathy. processes induced by tau protein requires phosphorylation
Exp Mol Med. 2017;49(5):e333. of serine 262 and 356 in the repeat domain and is inhibited
by phosphorylation in the proline-rich domains. Mol Biol
doi: 10.1038/emm.2017.56 Cell. 1999;10(3):727-740.
36. Kondo A, Shahpasand K, Mannix R, et al. Antibody against doi: 10.1091/mbc.10.3.727
early driver of neurodegeneration cis P-tau blocks brain
injury and tauopathy. Nature. 2015;523(7561):431-436. 46. Ksiezak-Reding H, Pyo HK, Feinstein B, Pasinetti GM. Akt/
PKB kinase phosphorylates separately Thr212 and Ser214
doi: 10.1038/nature14658 of tau protein in vitro. Biochim Biophys Acta. 2003;1639(3):
37. Niziolek GM, Hoehn RS, Seitz AP, et al. The role of acid 159-168.
sphingomyelinase inhibition in repetitive mild traumatic doi: 10.1016/j.bbadis.2003.09.001
brain injury. J Surg Res. 2021;259:296-304.
47. Strang KH, Goodwin MS, Riffe C, et al. Generation and
doi: 10.1016/j.jss.2020.09.034 characterization of new monoclonal antibodies targeting the
38. Niziolek GM, Boudreau RM, Baker J, et al. Acid PHF1 and AT8 epitopes on human tau. Acta Neuropathol
sphingomyelinase inhibition mitigates histopathological Commun. 2017;5(1):58.
and behavioral changes in a murine model of traumatic doi: 10.1186/s40478-017-0458-0
brain injury. J Neurotrauma. 2020;37(17):1902-1909.
48. Garcia-Sierra F, Ghoshal N, Quinn B, Berry RW, BinderLI.
doi: 10.1089/neu.2019.6436 Conformational changes and truncation of tau protein
39. Rehman SU, Ahmad A, Yoon GH, Khan M, Abid MN, during tangle evolution in Alzheimer’s disease. J Alzheimers
Kim MO. Inhibition of c-Jun N-terminal kinase protects Dis. 2003;5(2):65-77.
against brain damage and improves learning and memory doi: 10.3233/jad-2003-5201
after traumatic brain injury in adult mice. Cereb Cortex.
2018;28(8):2854-2872. 49. Tagge CA, Fisher AM, Minaeva OV, et al. Concussion,
microvascular injury, and early tauopathy in young athletes
doi: 10.1093/cercor/bhx164 after impact head injury and an impact concussion mouse
40. Arakhamia T, Lee CE, Carlomagno Y, et al. Posttranslational model. Brain. 2018;141(2):422-458.
modifications mediate the structural diversity of tauopathy doi: 10.1093/brain/awx350
strains. Cell. 2020;180(4):633-644.e612.
50. Albayram O, Kondo A, Mannix R, et al. Cis P-tau is induced
doi: 10.1016/j.cell.2020.01.027
in clinical and preclinical brain injury and contributes to
41. Regalado-Reyes M, Furcila D, Hernandez F, Avila J, post-injury sequelae. Nat Commun. 2017;8(1):1000.
DeFelipe J, Leon-Espinosa G. Phospho-tau changes in
the human CA1 during Alzheimer’s disease progression. doi: 10.1038/s41467-017-01068-4
J Alzheimers Dis. 2019;69(1):277-288. 51. Nakamura K, Greenwood A, Binder L, et al. Proline
isomer-specific antibodies reveal the early pathogenic tau
doi: 10.3233/JAD-181263
conformation in Alzheimer’s disease. Cell. 2012;149(1):
42. Carroll T, Guha S, Nehrke K, Johnson GVW. Tau post- 232-244.
translational modifications: Potentiators of selective
vulnerability in sporadic Alzheimer’s disease. Biology doi: 10.1016/j.cell.2012.02.016
(Basel). 2021;10(10):1047. 52. Nakamura K, Zhen Zhou X, Ping Lu K. Cis phosphorylated

Volume 3 Issue 3 (2024) 10 doi: 10.36922/an.3213